At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category......
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments. The next......
MSD, a unit of US drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs......
Delhi High Court on Wednesday posted for April 12 an appeal filed by US pharmaceuticals major Merck Sharp and Dohme against the single judge bench order refusing to restrain Indian firm Glenmark......
Sun Pharmaceutical Industries Ltd and MSD in India said they have entered into a partnership to market diabetes drugs Sitagliptin and Sitaglipitin plus Metformin in the Indian market.Under the......